2. Search Result
Search Result
Isoforms Recommended: p38α
Results for "

p38α-MAPK

" in MedChemExpress (MCE) Product Catalog:

41

Inhibitors & Agonists

1

Natural
Products

1

Antibodies

Art. -Nr. Produktname Target Forschungsgebiete Chemical Structure
  • HY-10401
    VX-702
    4 Publications Verification

    		 p38 MAPK Autophagy Inflammation/Immunology
    VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β .
    VX-702
  • HY-N0841
    Bruceine A
    3 Publications Verification

    Dihydrobrusatol; NSC310616

    		 Parasite NF-κB p38 MAPK Phosphatase Apoptosis Infection Cancer
    Bruceine A (Dihydrobrusatol) is a natural quassinoid. Bruceine A is an inhibitor of parasites, NF-κB, and PFKFB4 (Kd: 44 nM). Bruceine A is an activator of P38α MAPK. Bruceine A has antiparasitic activity. Bruceine A has antitumor activity and inhibits cancer cell migration. Bruceine A blocks the cell cycle and induces apoptosis. Bruceine A can be used in parasites, pancreatic cancer, and breast cancer research .
    Bruceine A
  • HY-120111
    MW-150

    MW01-18-150SRM

    		 p38 MAPK Autophagy Neurological Disease Inflammation/Immunology
    MW150 (MW01-18-150SRM) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a Ki of 101 nM. MW-150 inhibits the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia .
    MW-150
  • HY-10406
    Talmapimod
    3 Publications Verification

    SCIO-469

    		 p38 MAPK TNF Receptor Interleukin Related VEGFR Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Talmapimod (SCIO-469) is an orally active and selective inhibitor of p38α MAPK with an IC50 of 9 nM. Talmapimod inhibits the secretion of inflammatory factors (such as TNFα, IL-1β, IL-6, and VEGF) by suppressing the p38α MAPK pathway, and it also inhibits angiogenesis and osteoclast activation. Talmapimod inhibits the growth of multiple myeloma cells and induces apoptosis. Talmapimod can be used to study various hematological malignancies (such as multiple myeloma, myelodysplastic syndrome) .
    Talmapimod
  • HY-111820
    CK1-IN-1

    		Casein Kinase p38 MAPK Cardiovascular Disease
    CK1-IN-1 (Compound 1c) is a casein kinase 1 (CK1) inhibitor with IC50 values of 15 nM and 16 nM for CK1δ and CK1ε, respectively. CK1-IN-1 inhibits p38α MAPK with an IC50 of 73 nM. CK1-IN-1 can be used to study cardiomyogenesis .
    CK1-IN-1
  • HY-18874
    p38-α MAPK-IN-1
    2 Publications Verification

    		 p38 MAPK Autophagy Others
    p38-α MAPK-IN-1 is an inhibitor of MAPK14 (p38-α), with IC50 of 2300 nM in EFC displacement assay, and 5500 nM in HTRF assay .
    p38-α MAPK-IN-1
  • HY-112401
    p38 MAP Kinase Inhibitor IV

    		p38 MAPK Inflammation/Immunology
    p38 MAP Kinase Inhibitor IV is a highly specific ATP-competitive p38α MAPK inhibitor with IC50s of 0.13 and 0.55 μM for p38α and p38β MAPK, respectively .
    p38 MAP Kinase Inhibitor IV
  • HY-W015445
    SD-169

    		p38 MAPK Metabolic Disease
    SD-169 is an orally active ATP-competitive inhibitor of p38α MAPK, with an IC50 of 3.2 nM. SD-169 also weakly inhibits p38β MAPK with an IC50 of 122 nM. SD-169 prevents the development and progression of diabetes by inhibiting T cell infiltration and activation .
    SD-169
  • HY-14305A
    BMS-582949 hydrochloride
    2 Publications Verification

    		 p38 MAPK Autophagy Inflammation/Immunology
    BMS-582949 hydrochloride is an orally active and highly selective p38α MAPK inhibitor, with an IC50 of 13 nM. BMS-582949 hydrochloride displays a significantly improved pharmacokinetic profile and is effective in inflammatory disease .
    BMS-582949 hydrochloride
  • HY-145564
    Emprumapimod

    PF-07265803

    		 p38 MAPK Cardiovascular Disease Inflammation/Immunology
    Emprumapimod (PF-07265803) is a potent, orally active and selective inhibitor of p38α MAPK directly inhibits LPS-induced IL-6 production from RPMI-8226 cell (IC50=100 pM). Emprumapimod can be used for the research of dilated cardiomyopathy and acute inflammatory pain .
    Emprumapimod
  • HY-131335
    p38α inhibitor 2

    		p38 MAPK Inflammation/Immunology
    p38α inhibitor 2 is a highly potent and selective p38α MAPK inhibitor, with a pIC50 of 9.6. p38α inhibitor 2 inhibits the hERG ion channel (IC50=27 μM) and shows a promising selectivity profile when tested in a panel of 51 other protein kinases (<30% inhibition at 10 μM concentration) and a panel of 141 other biological targets .
    p38α inhibitor 2
  • HY-161462
    ERK2/p38α MAPK-IN-1

    		ERK p38 MAPK Cancer
    ERK2/p38α MAPK-IN-1 (Compound 1, In silico Hit-2) is a potent and selective ERK2 and p38α MAPK inhibitor, with an IC50 of 82 μM for ERK2. ERK2/p38α MAPK-IN-1 binds to the allosteric site of ERK2 and p38α MAPK in distinct manners. ERK2/p38α MAPK-IN-1 can be used for the research of type 2 diabetes .
    ERK2/p38α MAPK-IN-1
  • HY-108645
    AL 8697

    		p38 MAPK Autophagy Inflammation/Immunology
    AL 8697 is a specific and orally active p38α MAPK inhibitor with an IC50 of 6 nM. AL 8697 displays 14-fold greater inhibition of p38α compared to p38β (IC50=82 nM), and 300-fold selectivity for p38α over a panel of 91 kinases. Anti-inflammatory activity .
    AL 8697
  • HY-175655
    BChE/p38-α MAPK-IN-1

    		p38 MAPK Cholinesterase (ChE) Interleukin Related Neurological Disease Inflammation/Immunology
    BChE/p38-α MAPK-IN-1 is a selective dual inhibitor of hBChE (IC50 = 772 nM) and p38α MAPK (IC50 = 191 nM). BChE/p38-α MAPK-IN-1 reduces the production of pro-inflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α) in cells. BChE/p38-α MAPK-IN-1 improves Scopolamine (HY-N0296)-induced cognitive impairment, as well as alleviates LPS (HY-D1056)-induced spatial learning impairment and exerts anti-neuroinflammatory effects in mice. BChE/p38-α MAPK-IN-1 can be used for the study of Alzheimer’s disease (AD) by targeting both cholinergic deficit and neuroinflammation .
    BChE/p38-α MAPK-IN-1
  • HY-162364
    p38-α MAPK-IN-7

    		p38 MAPK Neurological Disease
    p38-α MAPK-IN-7 (compound 4) is a p38α-MAPK inhibitor with an IC50 value of 98.7 nM. p38-α MAPK-IN-7 protects neuronal cells from dexamethasone-induced ROS production .
    p38-α MAPK-IN-7
  • HY-178433
    BChE/p38-α MAPK-IN-2

    		Cholinesterase (ChE) p38 MAPK Neurological Disease
    BChE/p38-α MAPK-IN-2 is a BChE and p38-α MAPK dual inhibitor. BChE/p38-α MAPK-IN-2 inhibits hBChE with an IC50 of 5.1 nM, showing 1000-fold selectivity over hAChE. BChE/p38-α MAPK-IN-2 inhibits p38α MAPK with an IC50 of 8.12 μM. BChE/p38-α MAPK-IN-2 exhibits neuroprotective effect and can be used for the research of neurological disease, such as Alzheimer’s disease .
    BChE/p38-α MAPK-IN-2
  • HY-10401R
    VX-702 (Standard)

    		Reference Standards p38 MAPK Autophagy Inflammation/Immunology
    VX-702 (Standard) is the analytical standard of VX-702. This product is intended for research and analytical applications. VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β .
    VX-702 (Standard)
  • HY-18759
    BMS-751324

    		p38 MAPK TNF Receptor Inflammation/Immunology
    BMS-751324 is a p38α MAPK inhibitor. BMS-751324 equips a precursor of carbamyl-methyl linkage, containing esters and phosphate functional groups derived from hydroxyphenylacetic acid (HPA). BMS-751324 effectively inhibits foot swelling and LPS-induced TNFα production in an arthritic rat model .
    BMS-751324
  • HY-120111A
    MW-150 hydrochloride

    MW01-18-150SRM hydrochloride

    		 p38 MAPK Autophagy Neurological Disease Inflammation/Immunology
    MW-150 hydrochloride (MW01-18-150SRM hydrochloride) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a Ki of 101 nM. MW-150 hydrochloride (MW01-18-150SRM hydrochloride) inhibits the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia .
    MW-150 hydrochloride
  • HY-146032
    p38-α MAPK-IN-4

    		p38 MAPK Neurological Disease Inflammation/Immunology
    p38-α MAPK-IN-4 (Compound 69) is a selective p38α MAPK inhibitor with an IC50 of 1.5 µM. p38-α MAPK-IN-4 rapidly and strongly prevents the development of mechanical allodynia (MA) in vivo .
    p38-α MAPK-IN-4
  • HY-171301
    p38α MAPK/CK1δ inhibitor-1

    		p38 MAPK Casein Kinase Inflammation/Immunology
    p38α MAPK/CK1δ inhibitor-1 (Compound 3) exhibits inhibitory activity against p38α MAPK and CK1δ with IC50s of 0.185 µM and 0.089 µM .
    p38α MAPK/CK1δ inhibitor-1
  • HY-114422
    ARRY-371797

    		Cholinesterase (ChE) p38 MAPK Neurological Disease
    ARRY-371797 is a potent and orally active p38α MAPK and BChE inhibitor with IC50 values of 12.0, 0.13, ＞100 µM for p38α MAP, hBChE, hAChE, respectively. ARRY-371797 has the potential for the research of Alzheimer’s disease .
    ARRY-371797
  • HY-172100
    p38-α MAPK-IN-8

    		Apoptosis Reactive Oxygen Species (ROS) p38 MAPK Cancer
    p38-α MAPK-IN-8 (Compound 13) is a lipophilic cationic derivative. p38-α MAPK-IN-8 is cytotoxic to various tumor cells, and can induce cell cycle arrest, apoptosis, increase reactive oxygen species (ROS) production, and induce mitochondrial membrane potential depolarization. The antitumor activity of p38-α MAPK-IN-8 may be related to p38α MAPK pathway, which can be used in the study of cancer .
    p38-α MAPK-IN-8
  • HY-147518
    p38-α MAPK-IN-5

    		p38 MAPK Inflammation/Immunology
    p38-α MAPK-IN-5 (compound 4e) is a potent p38α inhibitor with IC50s of 0.1 nM, 0.2 nM, 944 nM, 4100 nM for p38α, p38 β, p38γ, p38δ, respectively. p38-α MAPK-IN-5 has anti-inflammatory effect. p38-α MAPK-IN-5 has the potential for asthma and chronic obstructive pulmonary disease (COPD) research .
    p38-α MAPK-IN-5
  • HY-161293
    p38-α MAPK-IN-6

    		p38 MAPK Cancer
    p38-α MAPK-IN-6 (compound 3a) is a p38α mitogen-activated protein kinase inhibitor .
    p38-α MAPK-IN-6
  • HY-171297
    p38-α MAPK-IN-10

    		p38 MAPK Inflammation/Immunology
    p38-α MAPK-IN-10 (Compound 6) is the inhibitor for p38α with an IC50 of 4 nM .
    p38-α MAPK-IN-10
  • HY-120111B
    MW-150 dihydrochloride dihydrate

    MW01-18-150SRM dihydrochloride dihydrate

    		 p38 MAPK Autophagy Neurological Disease Inflammation/Immunology
    MW-150 dihydrochloride dihydrate (MW01-18-150SRM dihydrochloride dihydrate) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a Ki of 101 nM. MW-150 dihydrochloride dihydrate (MW01-18-150SRM dihydrochloride dihydrate) inhibits the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia .
    MW-150 dihydrochloride dihydrate
  • HY-145564A
    Emprumapimod hydrochloride

    PF-07265803 hydrochloride

    		 p38 MAPK Cardiovascular Disease Inflammation/Immunology
    Emprumapimod (PF-07265803) hydrochloride is an orally active and selective inhibitor of p38α MAPK. Emprumapimod hydrochloride can be used for the research of dilated cardiomyopathy and acute inflammatory pain .
    Emprumapimod hydrochloride
  • HY-10406A
    Talmapimod hydrochloride

    SCIO-469 hydrochloride

    		p38 MAPK TNF Receptor Interleukin Related VEGFR Apoptosis Cancer
    Talmapimod (SCIO-469) hydrochloride is an orally active and selective inhibitor of p38α MAPK with an IC50 of 9 nM. Talmapimod hydrochloride inhibits the secretion of inflammatory factors (such as TNFα, IL-1β, IL-6, and VEGF) by suppressing the p38α MAPK pathway, and it also inhibits angiogenesis and osteoclast activation. Talmapimod hydrochloride inhibits the growth of multiple myeloma cells and induces apoptosis. Talmapimod hydrochloride can be used to study various hematological malignancies (such as multiple myeloma, myelodysplastic syndrome) .
    Talmapimod hydrochloride
  • HY-144697
    p38 MAPK-IN-3

    		p38 MAPK Apoptosis Reactive Oxygen Species (ROS) Cancer
    p38 MAPK-IN-3 (Compound 2c) is a p38α MAPK inhibitor. p38 MAPK-IN-3 has antitumor activities and induces apoptosis and ROS .
    p38 MAPK-IN-3
  • HY-171300
    p38α inhibitor 8

    		p38 MAPK Casein Kinase Inflammation/Immunology
    p38α inhibitor 8 (Compound 1) exhibits inhibitory activity against p38α MAPK and CK1δ with IC50 of 0.21 µM and 0.202 µM [1]>.
    p38α inhibitor 8
  • HY-171254
    p38-α MAPK-IN-9

    		p38 MAPK Inflammation/Immunology
    p38-α MAPK-IN-9 (Compound 25a) is a p38-α MAPK inhibitor (Ki: 0.057 nM). p38-α MAPK-IN-9 inhibits LPS (HY-D1056) induced TNFα production in hPBMCs (IC50: 18 nM) .
    p38-α MAPK-IN-9
  • HY-120796
    MW108 hydrochloride

    MW01-11-108SRM hydrochloride

    		 p38 MAPK Neurological Disease
    MW108 (MW01-11-108SRM) hydrochloride is a selective and CNS-penetrant p38αMAPK inhibitor with a Ki of 114 nM. MW108 hydrochloride ameliorates beta-amyloid induced synaptic and cognitive dysfunction .
    MW108 hydrochloride
  • HY-180824
    p38-α MAPK-IN-11

    		p38 MAPK Neurological Disease
    P38-α MAPK-IN-11 (Compound 4C) is a selective inhibitor of P38α MAPK that can cross the blood-brain barrier with an IC50 value of 43 nM. P38-α MAPK-IN-11 has extremely low inhibitory activity against other MAPK subtypes, namely p38β, p38γ, and p38δ, with IC50 values of > 100 nM, > 100 nM, and 48.6 mM respectively. P38-α MAPK-IN-11 exhibits outstanding neuroprotective effects and anti-neuroinflammatory effects in Alzheimer's disease-like rat models. P38-α MAPK-IN-11 can be used for the study of Alzheimer's disease .
    p38-α MAPK-IN-11
  • HY-183531
    p38 MAP Kinase-IN-4

    		p38 MAPK Inflammation/Immunology
    p38 MAP Kinase-IN-4 is a p38α MAPK inhibitor with an IC50 of 40.5 nM. p38 MAP Kinase-IN-4 is applicable to inflammation-related research .
    p38 MAP Kinase-IN-4
  • HY-10406B
    rel-Talmapimod hydrochloride

    rel-SCIO-469 hydrochloride

    		 p38 MAPK TNF Receptor Interleukin Related VEGFR Apoptosis Cancer
    rel-Talmapimod (rel-SCIO-469) hydrochloride is an orally active and selective inhibitor of p38α MAPK with an IC50 of 9 nM. rel-Talmapimod hydrochloride inhibits the secretion of inflammatory factors (such as TNFα, IL-1β, IL-6, and VEGF) by suppressing the p38α MAPK pathway, and it also inhibits angiogenesis and osteoclast activation. rel-Talmapimod hydrochloride inhibits the growth of multiple myeloma cells and induces apoptosis. rel-Talmapimod hydrochloride can be used to study various hematological malignancies (such as multiple myeloma, myelodysplastic syndrome) .
    rel-Talmapimod hydrochloride
  • HY-10406R
    Talmapimod (Standard)

    SCIO-469 (Standard)

    		 Reference Standards p38 MAPK TNF Receptor Interleukin Related VEGFR Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Talmapimod (Standard) is the analytical standard of Talmapimod (HY-10406). This product is intended for research and analytical applications. Talmapimod (SCIO-469) is an orally active and selective inhibitor of p38α MAPK with an IC50 of 9 nM. Talmapimod inhibits the secretion of inflammatory factors (such as TNFα, IL-1β, IL-6, and VEGF) by suppressing the p38α MAPK pathway, and it also inhibits angiogenesis and osteoclast activation. Talmapimod inhibits the growth of multiple myeloma cells and induces apoptosis. Talmapimod can be used to study various hematological malignancies (such as multiple myeloma, myelodysplastic syndrome) .
    Talmapimod (Standard)
  • HY-W015445R
    SD-169 (Standard)

    		Reference Standards p38 MAPK Metabolic Disease
    SD-169 is an orally active ATP-competitive inhibitor of p38α MAPK, with an IC50 of 3.2 nM. SD-169 also weakly inhibits p38β MAPK with an IC50 of 122 nM. SD-169 prevents the development and progression of diabetes by inhibiting T cell infiltration and activation .
    SD-169 (Standard)
  • HY-183042
    p38α-IN-12

    		p38 MAPK Cancer
    p38α-IN-12 is an orally bioavailable p38α MAPK inhibitor, with an IC50 of 0.11 nM and a Ki of 0.2 nM against human targets. p38α-IN-12 inhibits the production of TNFα in cellular systems and exerts in vivo efficacy in acute mouse models .
    p38α-IN-12
  • HY-182579
    CBS-3408

    		p38 MAPK TNF Receptor Interleukin Related Inflammation/Immunology
    CBS-3408 is an orally active p38α MAPK inhibitor. CBS-3408 inhibits the release of TNFα and IL-1β. CBS-3408 reduces the disease severity of arthritis in mice. CBS-3408 inhibits TNFα release in a rat endotoxemia model. CBS-3408 can be used in studies related to endotoxemia and arthritis .
    CBS-3408
  • HY-179451
    Apoptosis inducer 53

    		Apoptosis p38 MAPK Parasite Infection Inflammation/Immunology Cancer
    Apoptosis inducer 53 is an apoptosis inducer. Apoptosis inducer 53 can inhibit proliferation of human tumor cell lines (A549, HeLa, SW1573, T-47D, WiDr) with GI50 values of 2.5-9.1 μM. Apoptosis inducer 53 can induce cancer cells apoptosis and reduce colony formation. Apoptosis inducer 53 can activate p38α MAPK signaling and exerts anti-inflammatory effect. Apoptosis inducer 53 also shows anti-Leishmania donovani activity. Apoptosis inducer 53 can be used for the researches of cancer, infection and inflammation .
    Apoptosis inducer 53

Online-Anfrage

Your information is safe with us. * Required Fields.

Anrede

  

Country or Region *

Name des Antragstellers *

 

Name der Organisation *

Department *

     

E-Mail-Addresse *

 

Produktname *

Art. -Nr.

  

Requested quantity *

Telefonnummer *

     

Bemerkungen

Online-Anfrage

Inquiry Information

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent: